Mundipharma will be able to market Prestige BioPharma’s Tuznue (trastuzumab) biosimilar exclusively in “selected European countries” including Austria, Denmark, Finland, France, Norway, Portugal, Spain, Sweden and Switzerland upon approval, according to the terms of an agreement between the two companies.
Prestige had in late June announced positive results from a Phase III trial of the HD201 trastuzumab biosimilar candidate that it recently filed with the European Medicines Agency. (Also see "Henlius Has First ‘China-Developed’ Biosimilar Accepted For EMA Review" - Generics Bulletin, 25 June, 2019
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?